- Home
- LYFT vs BPMC Comparison
LYFT vs BPMC Comparison
Compare LYFT & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- BPMC
- Stock Information
- Founded
- LYFT 2007
- BPMC 2008
- Country
- LYFT United States
- BPMC United States
- Employees
- LYFT N/A
- BPMC N/A
- Industry
- LYFT Business Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- LYFT Consumer Discretionary
- BPMC Health Care
- Exchange
- LYFT Nasdaq
- BPMC Nasdaq
- Market Cap
- LYFT 6.3B
- BPMC 5.8B
- IPO Year
- LYFT 2019
- BPMC 2015
- Fundamental
- Price
- LYFT $16.10
- BPMC $128.35
- Analyst Decision
- LYFT Buy
- BPMC Buy
- Analyst Count
- LYFT 33
- BPMC 20
- Target Price
- LYFT $16.53
- BPMC $127.82
- AVG Volume (30 Days)
- LYFT 14.2M
- BPMC 3.6M
- Earning Date
- LYFT 08-06-2025
- BPMC 07-31-2025
- Dividend Yield
- LYFT N/A
- BPMC N/A
- EPS Growth
- LYFT N/A
- BPMC N/A
- EPS
- LYFT 0.14
- BPMC N/A
- Revenue
- LYFT $5,958,987,000.00
- BPMC $562,121,000.00
- Revenue This Year
- LYFT $14.15
- BPMC $44.46
- Revenue Next Year
- LYFT $12.81
- BPMC $32.78
- P/E Ratio
- LYFT $117.41
- BPMC N/A
- Revenue Growth
- LYFT 27.32
- BPMC 99.19
- 52 Week Low
- LYFT $8.93
- BPMC $73.04
- 52 Week High
- LYFT $19.07
- BPMC $128.52
- Technical
- Relative Strength Index (RSI)
- LYFT 59.28
- BPMC 74.59
- Support Level
- LYFT $15.58
- BPMC $128.06
- Resistance Level
- LYFT $16.46
- BPMC $128.52
- Average True Range (ATR)
- LYFT 0.54
- BPMC 0.28
- MACD
- LYFT 0.05
- BPMC -1.18
- Stochastic Oscillator
- LYFT 86.47
- BPMC 74.44
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.